A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly by Wing, Lindon M. H. et al.
 n engl j med 
 
348;7
 
www.nejm.org february 
 
13, 2003
 
583
 
The
 
 new england
journal 
 
of
 
 medicine
 
established in 1812
 
february
 
 
 
13
 
, 
 
2003
 
vol. 348 no. 7 
 
A Comparison of Outcomes with Angiotensin-Converting–Enzyme 
Inhibitors and Diuretics for Hypertension in the Elderly
 
Lindon M.H. Wing, M.B., B.S., Christopher M. Reid, Ph.D., Philip Ryan, M.B., B.S., Lawrence J. Beilin, M.D., 
Mark A. Brown, M.B., B.S., M.D., Garry L.R. Jennings, M.D., Colin I. Johnston, M.B., B.S., John J. McNeil, M.B., B.S., 
Graham J. Macdonald, M.D., John E. Marley, M.D., M.B., Ch.B., Trefor O. Morgan, M.B., B.S., 
and Malcolm J. West, M.B., B.S., for the Second Australian National Blood Pressure Study Group*
abstract
 
From the School of Medicine, Flinders Uni-
versity, Adelaide (L.M.H.W.); the Baker
Heart Research Institute, Melbourne
(C.M.R., G.L.R.J., C.I.J.); the Department
of Public Health, University of Adelaide,
Adelaide (P.R.); the Department of Medi-
cine, University of Western Australia, Perth
(L.J.B.); the Department of Nephrology, Uni-
versity of New South Wales, Sydney
(M.A.B.); the Department of Epidemiolo-
gy and Preventive Medicine, Monash Uni-
versity, Melbourne (J.J.M.); Merck Sharp
& Dohme, Sydney (G.J.M.); the Faculty of
Health, University of Newcastle, Newcas-
tle (J.E.M.); the Department of Physiology,
University of Melbourne, Melbourne
(T.O.M.); and the Department of Medi-
cine, University of Queensland, Brisbane
(M.J.W.) — all in Australia. Address re-
print requests to Dr. Reid at the Baker
Heart Research Institute, P.O. Box 6492,
St. Kilda Rd. Central, Melbourne, VIC
8008, Australia, or at chris.reid@baker.
edu.au.
*Investigators in the Second Australian
National Blood Pressure Study (ANBP2)
are listed in the Appendix.
N Engl J Med 2003;348:583-92.
 
Copyright © 2003 Massachusetts Medical Society.
 
background
 
Treatment of hypertension with diuretics, beta-blockers, or both leads to improved out-
comes. It has been postulated that agents that inhibit the renin–angiotensin system con-
fer benefit beyond the reduction of blood pressure alone. We compared the outcomes
in older subjects with hypertension who were treated with angiotensin-converting–
enzyme (ACE) inhibitors with the outcomes in those treated with diuretic agents.
 
methods
 
We conducted a prospective, randomized, open-label study with blinded assessment of
end points in 6083 subjects with hypertension who were 65 to 84 years of age and re-
ceived health care at 1594 family practices. Subjects were followed for a median of 4.1
years, and the total numbers of cardiovascular events in the two treatment groups were
compared with the use of multivariate proportional-hazards models.
 
results
 
At base line, the treatment groups were well matched in terms of age, sex, and blood
pressure. By the end of the study, blood pressure had decreased to a similar extent in both
groups (a decrease of 26/12 mm Hg). There were 695 cardiovascular events or deaths
from any cause in the ACE-inhibitor group (56.1 per 1000 patient-years) and 736 cardio-
vascular events or deaths from any cause in the diuretic group (59.8 per 1000 patient-
years; the hazard ratio for a cardiovascular event or death with ACE-inhibitor treatment
was 0.89 [95 percent confidence interval, 0.79 to 1.00]; P=0.05). Among male subjects,
the hazard ratio was 0.83 (95 percent confidence interval, 0.71 to 0.97; P=0.02); among
female subjects, the hazard ratio was 1.00 (95 percent confidence interval, 0.83 to 1.21;
P=0.98); the P value for the interaction between sex and treatment-group assignment
was 0.15. The rates of nonfatal cardiovascular events and myocardial infarctions de-
creased with ACE-inhibitor treatment, whereas a similar number of strokes occurred
in each group (although there were more fatal strokes in the ACE-inhibitor group).
 
conclusions
 
Initiation of antihypertensive treatment involving ACE inhibitors in older subjects, par-
ticularly men, appears to lead to better outcomes than treatment with diuretic agents, de-
spite similar reductions of blood pressure.
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lacebo-controlled studies of the
 
drug treatment of mild-to-moderate
 
 
 
hyper-
tension have demonstrated that the reduc-
tion of blood pressure is associated with a reduced
risk of cardiovascular events and death.
 
1-7 
 
This
benefit was first shown with diuretics, beta-block-
ers, or both as initial therapy.
 
1-6
 
 Since those studies
were conducted, newer classes of antihypertensive
agents, including angiotensin-converting–enzyme
(ACE) inhibitors, calcium-channel antagonists, and
angiotensin II antagonists, have become widely ac-
cepted into practice. When our study began, no data
were available indicating whether therapy involving
these newer agents would have the same benefit in
persons with hypertension. However, evidence of a
benefit of treatment with ACE inhibitors in the im-
provement of impaired cardiac function
 
8-10
 
 sug-
gested that they conferred additional benefit beyond
their ability to lower blood pressure, possibly be-
cause of effects on independent cardiovascular risk
factors.
 
11-13
 
 It had earlier been suggested that ex-
cessive activity of the renin–angiotensin system had
deleterious cardiovascular effects beyond its influ-
ence on blood pressure.
 
14
 
During the past three to four years, results have
been published of studies evaluating differences be-
tween regimens based on conventional agents and
regimens based on newer drugs in terms of out-
comes in hypertensive subjects.
 
15-18
 
 None of the
studies involving ACE inhibitors or calcium-channel
antagonists has yet demonstrated a clear difference
in outcome between treatment groups.
 
19
 
 The recent
Heart Outcomes Prevention Evaluation (HOPE)
study reported that ACE inhibitors confer a benefit
in terms of outcome despite the fact that they result
in little or no change in blood pressure in high-risk
subjects.
 
20
 
 Further supportive evidence comes from
the Losartan Intervention for Endpoint Reduction
(LIFE) study, which demonstrated that antihyper-
tensive therapy with the angiotensin II antagonist
losartan prevented more cardiovascular events
and deaths than did therapy with the beta-blocker
atenolol, which led to a similar reduction in blood
pressure.
 
21
 
Our study was undertaken to address the
question of possible regimen-specific benefit
with respect to the outcome of the treatment of
hypertension. We investigated whether there was
any difference in outcome between hypertensive
subjects who are actively treated with an ACE-inhib-
itor–based regimen and those treated with a diuret-
ic-based regimen. Unlike many previous studies,
our study enrolled older subjects with hyperten-
sion who had had few previous cardiovascular
events. The study was conducted at family practices
throughout Australia and thus reflects routine clin-
ical practice for the management of hypertension.
 
study design
 
The study design and recruitment strategies have
been published previously.
 
22-24
 
 In brief, the study
was conducted at 1594 family medical practices
throughout Australia, with the use of a prospective,
randomized, open-label design, with blinded as-
sessments of end points.
 
25
 
At screening, blood pressure was measured by
trained study nurses using a mercury sphygmoma-
nometer in all eligible subjects 65 to 84 years of
age.
 
26
 
 Suitable subjects had two subsequent study-
entry visits at least one week apart. In subjects who
were taking antihypertensive drugs, medication was
discontinued under medical supervision. Subjects
were required to be free of antihypertensive drugs
for at least one week before the study-entry visits.
 
criteria for inclusion and exclusion
 
Criteria for inclusion in the study were an average
systolic blood pressure, measured at the two study-
entry visits while the subject was sitting, of at least
160 mm Hg or an average diastolic blood pressure
of at least 90 mm Hg (if the systolic blood pressure
was at least 140 mm Hg); the absence of recent car-
diovascular events (within the previous six months);
and willingness to give informed consent. Criteria
for exclusion included any life-threatening illness,
contraindication to an ACE inhibitor or diuretic, a
plasma creatinine concentration of more than 2.5
mg per deciliter (221 µmol per liter), malignant hy-
pertension, or dementia. Subjects were randomly
assigned centrally by telephone to either ACE-inhib-
itor–based or diuretic-based treatment. Random-
ization began in April 1995 and was completed in
June 1998.
 
goals and treatments
 
Family practitioners were responsible for the man-
agement of antihypertensive therapy, which was to
conform to the randomized treatment assignment
and the study’s blood-pressure goals. The guide-
lines were based on the aim of achieving a reduction
of the systolic blood pressure by at least 20 mm Hg
to less than 160 mm Hg, with a further reduction to
p
methods
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less than 140 mm Hg if tolerated, and a reduction
of the diastolic blood pressure by at least 10 mm Hg
to less than 90 mm Hg, with a further reduction to
less than 80 mm Hg if tolerated.
 
24
 
 The ACE inhibi-
tor enalapril and the diuretic hydrochlorothiazide
were recommended as initial therapy; however, the
choice of the specific agent and dose was made by
the family practitioner.
To achieve the blood-pressure goals, the addition
of beta-blockers, calcium-channel blockers, and al-
pha-blockers was recommended in both groups.
 
24
 
Blood pressure was recorded annually by study
nurses and at each patient visit by the general practi-
tioner, using routine mercury sphygmomanometry.
Case records, hospital notes, and death certificates
were reviewed by study nurses for documentation of
end points every six months throughout the study.
 
end points
 
The primary end point was all cardiovascular events
or death from any cause. Both initial and subsequent
fatal and nonfatal cardiovascular events were in-
cluded. Cause-specific cardiovascular events in-
cluded the following: coronary events, including
myocardial infarction, sudden or rapid death from
cardiac causes, other deaths from coronary causes,
or coronary events associated with therapeutic pro-
cedures involving the coronary arteries; other car-
diovascular events, including heart failure, acute oc-
clusion of a major feeding artery in any vascular bed
other than cerebral or coronary, death from non-
coronary cardiac causes, dissecting or ruptured aor-
tic aneurysm, or death from vascular causes; and
cerebrovascular events, including stroke and tran-
sient ischemic attacks. An end-point committee
whose members were unaware of the treatment-
group assignments adjudicated all potential end
points.
 
approval, support, and conduct
of the study
 
The protocol was approved by the ethics committee
of the Royal Australian College of General Practi-
tioners and conducted in accordance with the Hel-
sinki Declaration.
 
27
 
 All subjects gave written in-
formed consent. The study is a project of the High
Blood Pressure Research Council of Australia that
was initiated, designed, and conducted by the inves-
tigators. Although it was funded by a joint venture
of the Commonwealth Government of Australia,
the National Health and Medical Research Coun-
cil, Merck Sharp & Dohme, and academic institu-
tions,
 
28
 
 all data analysis and writing were performed
independently by the publications committee, with-
out the involvement of representatives of Merck
Sharp & Dohme.
 
statistical analysis
 
Three thousand subjects were required in each
group for the study to achieve a power of 90 percent
to detect a 25 percent difference between the treat-
ment groups in the rate of cardiovascular events
during a five-year period, assuming a rate of 21
events per 1000 person-years in the diuretic group
 
4
 
and allowing for a 15 percent loss to follow-up. The
management committee decided to stop the trial
because the observed total number of events had
well exceeded the number required on the basis of
the estimate of sample size and because resources
became limited as the result of an extension of the
recruitment period. No comparison of the treatment
groups in terms of data on outcomes was performed
before the study was terminated.
Cox regression was used to model multiple times
to events, with the treatment-group assignment as
the principal predictor.
 
29,30
 
 An event was defined as
any cardiovascular event or death from any cause.
Robust estimates of variance were used to allow for
the clustering of subjects according to practitioner,
and potential confounding by risk factors was ex-
plored by analysts who were unaware of changes in
P values or of the direction of changes in esti-
mates.
 
31
 
 Only age and sex changed estimates sub-
stantially and were therefore adjusted for in the
model. Cumulative hazard functions were plotted to
check for proportional hazards. Simulation meth-
ods were used to validate estimates of the hazard ra-
tios and confidence intervals.
The two primary comparisons (all events and
any first events) were tested at the 0.05 level of sig-
nificance. Hazard ratios with 95 percent confidence
intervals and two-sided P values are presented. Haz-
ard ratios from secondary comparisons of cause-
specific first events and subgroups defined accord-
ing to sex are also shown with 95 percent confidence
intervals and P values unadjusted for multiple test-
ing, in order to facilitate comparisons with results
from other studies. However, the significance of
these secondary results should be judged cautious-
ly.
 
32
 
 The number needed to treat to avoid one addi-
tional event was estimated from survival functions
based on the proportional-hazards model.
 
33
 
 All re-
sults are based on intention-to-treat analyses.
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study subjects
 
A total of 54,288 subjects presented for the initial
screening visit. Fifty-eight percent (31,255) either
were currently being treated for hypertension
(25,926 subjects [48 percent]) or had untreated
blood pressure in the range specified by the eligi-
bility criteria (5329 subjects [10 percent]). A total of
8316 subjects (4682 previously treated subjects and
3634 untreated subjects) had study-entry visits, and
6083 subjects (95 percent of whom were white) were
subsequently randomly assigned to the ACE-inhib-
itor group (3044 subjects) or the diuretic group
(3039 subjects) (Fig. 1). Subjects were recruited over
a 3-year period and were followed for a median of
4.1 years, for a total of 24,702 patient-years of ob-
servation. As indicated in Figure 1, all subjects who
underwent randomization were included in the fi-
nal analysis. For subjects who were lost to follow-
up monitoring, we used the last available data; vital
status was ascertained for all but two subjects.
results
 
Figure 1. Summary of Screening, Randomization, and Loss to Follow-up.
 
ACE denotes angiotensin-converting enzyme.
54,288
Subjects screened for eligibility
31,255 (58%)
Hypertensive:
25,926 (48%) previously treated;
5329 (10%) untreated
6083
Underwent randomization:
3783 (62%) previously treated;
2300 (38%) untreated
3044 Assigned to ACE-inhibitor 
group
62% previously treated
3039 Assigned to diuretic group
62% previously treated
3044 
Included in intention-to-treat
analyses
66 Lost to follow-up 
monitoring
0 Without known 
vital status
99 Lost to follow-up 
monitoring
2 Without known 
vital status
3039 
Included in intention-to-treat
analyses
23,033 (42%)
Normotensive
8273 Ineligible
16,899 Declined to participate
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base-line data
 
The two treatment groups were similar in terms of
sex, age, blood pressure, body-mass index (the
weight in kilograms divided by the square of the
height in meters), plasma cholesterol concentra-
tion, tobacco and alcohol use, the level of physical
activity, and the extent of previous treatment with
antihypertensive drugs (Table 1). Eight percent of
subjects had previously had a coronary event, 5 per-
cent had previous cerebrovascular disease, and
7 percent had received a diagnosis of diabetes. Mean
(±SD) systolic blood pressure at entry was 168±13
mm Hg; mean diastolic blood pressure at entry was
91±8 mm Hg.
 
drug treatments
 
At randomization, 83 percent of subjects in both
treatment groups began to receive the treatment to
which they were assigned, with approximately 15
to 16 percent of subjects not receiving immediate
treatment. At the end of the study, 58 percent of sub-
jects randomly assigned to the ACE-inhibitor group
and 62 percent of those assigned to the diuretic
group were still receiving the assigned treatment.
Sixty-five percent of the subjects in the ACE-inhibi-
tor group and 67 percent of those in the diuretic
group were receiving monotherapy; 6 percent of the
subjects in the ACE-inhibitor group and 5 percent of
those in the diuretic group were receiving three or
more agents. Concomitant antihypertensive med-
ications (sometimes used in combination) included
calcium-channel blockers (in 22.9 percent of sub-
jects in the ACE-inhibitor group and 24.9 percent of
subjects in the diuretic group), beta-blockers (10.8
percent and 13.7 percent, respectively), and angio-
tensin-receptor blockers (14.0 percent and 12.4 per-
cent, respectively).
 
blood pressure
 
At year 1, blood pressure had decreased by 20/9
mm Hg in the ACE-inhibitor group and 22/9 mm Hg
in the diuretic group; at year 2, it had decreased by
23/10 mm Hg in the ACE-inhibitor group and 24/10
mm Hg in the diuretic group; and at year 5, it had
decreased by 26/12 mm Hg in both groups (Fig. 2).
These were significant and clinically relevant reduc-
tions from base-line values. There were no differ-
ences between the groups in the change in diastolic
blood pressure at any time point. The pattern of
blood-pressure reduction with the two treatments
was similar among men and among women.
 
outcomes
 
The overall rates of all cardiovascular events or
death in the two treatment groups are shown in Ta-
ble 2. The hazard ratio for all cardiovascular events
or death from any cause among subjects in the
ACE-inhibitor group as compared with those in the
diuretic group was 0.89 (95 percent confidence in-
terval, 0.79 to 1.00; P=0.05); in other words, there
was an 11 percent reduction in the total burden of
 
* Plus–minus values are means ±SD. Coronary heart disease included myocardial in-
farction, angina, coronary-artery bypass grafting, and percutaneous transluminal cor-
onary angioplasty; cerebrovascular disease included stroke and transient ischemic 
attack. The blood-pressure grade was according to the criteria of the World Health 
Organization and the International Society of Hypertension.
 
31
 
 Because of rounding, 
not all percentages total 100. ACE denotes angiotensin-converting enzyme.
† The body-mass index is the weight in kilograms divided by the square of the height 
 
in meters.
 
Table 1. Base-Line Characteristics of the Subjects.*
Characteristic
ACE-Inhibitor Group
(N=3044)
Diuretic Group
(N=3039)
All Subjects
(N=6083)
 
Sex (%)
Male
Female
50
50
48
52
49
51
Age
Mean (yr)
65–74 yr (%)
75–84 yr (%)
72.0
70
30
71.9
70
30
71.9
70
30
Blood pressure at random-
ization (mm Hg)
Systolic
Diastolic
167±13
91±8
168±13
91±8
168±13
91±8
Blood-pressure grade (%)
1
2
3
20
65
15
18
66
15
19
66
15
Previously treated (%) 62 62 62
Body-mass index† 27±4 27±4 27±4
Smoking status (%)
Current
Previous
7
46
7
45
7
45
Alcohol use (%)
Current
Previous
74
6
72
7
73
6
Physically active (%) 78 76 77
Coronary heart disease (%) 8 8 8
Cerebrovascular disease (%) 5 4 5
Diabetes mellitus (%) 8 7 7
Hypercholesterolemia (%)
Receiving lipid-lowering 
drugs
38
13
36
13
37
13
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cardiovascular events or death from any cause. The
difference between treatment groups appeared ear-
ly and remained consistent throughout the duration
of the study. From a clinical perspective, 32 subjects
of either sex in this age group or 23 men would need
to be given ACE-inhibitor–based therapy in order
to prevent one additional first cardiovascular event
or death within the first five years after treatment
began.
There were almost twice as many events in male
subjects (907 events) as in female subjects (524
events). The beneficial effects of ACE-inhibitor
treatment were more evident in male subjects,
among whom there was a 17 percent reduction in
the rates of both all cardiovascular events and first
cardiovascular events (hazard ratio for both end
points, 0.83 [95 percent confidence interval, 0.71 to
0.97]; P=0.02) (Fig. 3). Among female subjects, the
hazard ratio for all cardiovascular events and first
cardiovascular events was 1.00 (95 percent confi-
dence interval for all events, 0.83 to 1.21; 95 percent
confidence interval for first events, 0.83 to 1.20;
 
Figure 2. Systolic and Diastolic Blood Pressure after Randomization.
 
The numbers above the curves indicate the numbers of subjects whose 
blood pressure was measured. ACE denotes angiotensin-converting 
enzyme.
B
lo
od
 P
re
ss
ur
e 
(m
m
 H
g)
Years since Randomization
170
160
150
140
130
95
90
85
80
75
0
0 1 2 3 4 5
ACE inhibitor
DiureticSystolic
Diastolic
6083
6083
6035
6035
5583
5585
5487
5487
4320
4323
1183
1183
 
* Hazard ratios are for the event in the group assigned to angiotensin-converting–enzyme (ACE) inhibitors as compared with the 
diuretic group and are adjusted for age and sex. CI denotes confidence interval.
† Myocardial infarction is a subcategory of coronary events; heart failure is a subcategory of other cardiovascular events; and 
stroke is a subcategory of cerebrovascular events. Patients were counted once for each type of first cardiovascular event they had, 
 
but patients who had more than one type of event were counted only once for the overall category of first cardiovascular event.
 
Table 2. Primary End Points and Cause-Specific First Events.*
Event
ACE-Inhibitor Group
(N=3044)
Diuretic Group
(N=3039)
Hazard Ratio
(95% CI)
P
Value
 
No. of
Events
Rate per 1000
Patient-yr
No. of
Events
Rate per 1000
Patient-yr
 
Primary end points
 
All cardiovascular events or death from 
any cause
695 56.1 736 59.8 0.89 (0.79–1.00) 0.05
First cardiovascular event or death from 
any cause
490 41.9 529 45.7 0.89 (0.79–1.01) 0.06
Death from any cause 195 15.7 210 17.1 0.90 (0.75–1.09) 0.27
 
Cause-specific first events
 
First cardiovascular event† 394 33.7 429 37.1 0.88 (0.77–1.01) 0.07
Coronary event 173 14.3 195 16.2 0.86 (0.70–1.06) 0.16
Myocardial infarction 58 4.7 82 6.7 0.68 (0.47–0.98) 0.04
Other cardiovascular event 134 11.0 144 11.9 0.90 (0.71–1.14) 0.36
Heart failure 69 5.6 78 6.4 0.85 (0.62–1.18) 0.33
Cerebrovascular event 152 12.5 163 13.6 0.90 (0.73–1.12) 0.35
Stroke 112 9.2 107 8.8 1.02 (0.78–1.33) 0.91
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P=0.98 for both comparisons). The P value for the
interaction between sex and treatment-group as-
signment was 0.15 for all cardiovascular events or
death from any cause and 0.14 for first cardiovas-
cular events.
The hazard ratio for all first cardiovascular events
in the ACE-inhibitor group as compared with the
diuretic group was 0.88 (95 percent confidence in-
terval, 0.77 to 1.01; P=0.07); this ratio represents a
12 percent reduction over the study period (Table 2).
There was no significant difference between treat-
ments in terms of the rate of first coronary events,
but there was a reduction in the rate of first myocar-
dial infarctions in the ACE-inhibitor group: the ad-
justed hazard ratio was 0.68 (95 percent confidence
interval, 0.47 to 0.98; P=0.04).
There was no significant difference between the
two treatment groups in the rates of fatal cardio-
vascular or noncardiovascular events (Table 3). The
rates of cause-specific fatal events did not differ sig-
nificantly between the treatment groups, with the
exception of the rate of fatal strokes, which was
higher with ACE-inhibitor treatment (adjusted haz-
ard ratio, 1.91 [95 percent confidence interval, 10.4
to 3.50]; P=0.04).
There was a 14 percent reduction in the rate of
first nonfatal cardiovascular events with ACE-inhib-
itor treatment (adjusted hazard ratio, 0.86 [95 per-
cent confidence interval, 0.74 to 0.99]; P=0.03) and
a 32 percent reduction in the rate of first nonfatal
myocardial infarctions (adjusted hazard ratio, 0.68
[95 percent confidence interval, 0.47 to 0.99];
P=0.05) (Table 3). There was no significant differ-
ence between treatments in terms of any other first
nonfatal cardiovascular events. As with the main
outcomes of the study, differences between treat-
ment groups in cause-specific fatal and nonfatal
events were observed only among male subjects.
Our study has demonstrated that outcomes are bet-
ter when hypertension in the elderly is treated with
an ACE inhibitor than when it is treated with a di-
uretic agent, with the difference being observed pri-
marily among male subjects. In contrast to other
recent trials in the elderly, the subjects in this trial
were relatively healthy and active and, overall, had
few previous cardiovascular events; one would
therefore expect the benefit to be smaller than that
found in the other trials, but the results should be
more generally applicable to elderly populations.
The benefit was a reduction in the rate of total car-
diovascular events or death from any cause, with a
discussion
 
Figure 3. Primary End Points among All Subjects, Male Subjects, and Female Subjects.
 
ACE denotes angiotensin-converting enzyme, and CI confidence interval. 
First cardiovascular event or death from any cause
Death from any cause
ACE Inhibitors Superior
P ValueHazard Ratio (95% Cl)End Point
All Subjects
Diuretics Superior
0.2 1.0 5.0
All cardiovascular events or death from any cause 0.89 (0.79–1.00)
0.89 (0.79–1.01)
0.90 (0.75–1.09)
0.05
0.06
0.27
First cardiovascular event or death from any cause
Death from any cause
ACE Inhibitors Superior
P ValueHazard Ratio (95% Cl)End Point
Male Subjects
Diuretics Superior
0.2 1.0 5.0
All cardiovascular events or death from any cause 0.83 (0.71–0.97)
0.83 (0.71–0.97)
0.83 (0.66–1.06)
0.02
0.02
0.14
First cardiovascular event or death from any cause
Death from any cause
ACE Inhibitors Superior
P ValueHazard Ratio (95% Cl)End Point
Female Subjects
Diuretics Superior
0.2 1.0 5.0
All cardiovascular events or death from any cause 1.00 (0.83–1.21)
1.00 (0.83–1.20)
1.01 (0.76–1.35)
0.98
0.98
0.94
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particular reduction in the rate of nonfatal events.
There was also a reduced likelihood of a first car-
diovascular event or death.
Since we conducted the study in the family-
practice setting, our results reflect the probable ef-
fects among relatively healthy elderly persons with
hypertension in typical care settings. For example,
15 to 16 percent of subjects in both groups did not
immediately begin receiving medication, because
the family practitioner and the patient preferred
to delay treatment. Faced with an elderly hyperten-
sive patient with blood pressure just above 140/90
mm Hg (satisfying the criteria for study entry), a pri-
mary care physician may choose not to begin treat-
ment immediately despite established evidence of
benefit. However, all but 3 to 4 percent of subjects
were treated during the study. The finding that ap-
proximately 60 percent of subjects continued to re-
ceive the treatment to which they were assigned for
the duration of the study is consistent with findings
in other trials focused on hypertension in elderly
subjects and suggests what is likely to happen in
practice.
 
4,7,15
 
Three other published studies have compared
ACE-inhibitor–based therapy for hypertension with
conventional treatment: the Swedish Trial in Old
Patients with Hypertension-2 (STOP-2) study,
 
15
 
the Captopril Prevention Project (CAPPP),
 
16
 
 and
the United Kingdom Prospective Diabetes Study
(UKPDS).
 
34
 
 The results of these studies are consis-
tent with our findings, but our trial also demon-
strates differences of a clinically and statistically
relevant magnitude. The design of the trial, the en-
try criteria, the definition of end points, and the al-
pha error are factors that may have contributed to
the differences between our findings and those of
other studies. Although a prospective meta-analysis
has concluded that “there were no detectable differ-
ences between randomized groups in the risks of
any of the outcomes studied,”
 
19
 
 our study and the
Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT)
 
35
 
 will be in-
 
* Myocardial infarction is a subcategory of coronary events; heart failure is a subcategory of other cardiovascular events. For non-
fatal events, patients were counted once for each type of event they had, but patients who had more than one type of event were 
counted only once for the overall category of nonfatal cardiovascular events. Hazard ratios are for the event in the group assigned 
to angiotensin-converting–enzyme (ACE) inhibitors as compared with the diuretic group and are adjusted for age and sex. CI de-
 
notes confidence interval.
 
Table 3. Cause-Specific First Events (Fatal and Nonfatal).*
Event
ACE-Inhibitor Group
(N=3044)
Diuretic Group
(N=3039)
Hazard Ratio
(95% CI)
P
Value
 
No. of
Events
Rate per 1000
Patient-yr
No. of
Events
Rate per 1000
Patient-yr
Fatal events
Cardiovascular 84 6.8 82 6.7 0.99 (0.72–1.35) 0.94
Coronary event 40 3.2 52 4.2 0.74 (0.49–1.11) 0.14
Myocardial infarction 9 0.7 11 0.9 0.79 (0.31–1.99) 0.61
Other cardiovascular event 15 1.2 15 1.2 0.95 (0.46–1.96) 0.89
Heart failure 2 0.2 8 0.7 0.24 (0.03–1.94) 0.18
Stroke 29 2.3 15 1.2 1.91 (1.04–3.50) 0.04
Noncardiovascular 111 9.0 128 10.4 0.84 (0.66–1.08) 0.18
Nonfatal cardiovascular events 338 28.9 380 32.8 0.86 (0.74–0.99) 0.03
Coronary event 141 11.6 149 12.4 0.92 (0.73–1.16) 0.49
Myocardial infarction 50 4.1 71 5.8 0.68 (0.47–0.99) 0.05
Other cardiovascular event 120 9.9 137 11.3 0.84 (0.66–1.07) 0.17
Heart failure 68 5.5 77 6.3 0.85 (0.62–1.17) 0.32
Stroke 91 7.5 94 7.8 0.93 (0.70–1.26) 0.65
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on March 30, 2017. For personal use only. No other uses without permission. 
 Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
348;7
 
www.nejm.org february 
 
13, 2003
 
ace inhibitors vs. diuretics for hypertension
 
591
 
cluded in the next cycle of this meta-analysis, which
will provide a more definitive comparison of out-
comes with ACE-inhibitor–based and diuretic-
based regimens.
 
19,36,37
 
The observation in our study that the relative
benefits of an ACE-inhibitor–based regimen were
restricted to men is of interest but should be inter-
preted with caution, since it represents a post hoc
analysis of the data and requires confirmation. The
observation that the rate of events among male sub-
jects was almost twice that among female subjects
is highly consistent with current data on morbidity
and mortality.
 
38
 
 Men have a higher cardiovascular
risk than women, and ACE-inhibitor treatment may
be of particular advantage in subjects with high car-
diovascular risk because of factors that influence the
atherosclerotic process, such as stability of plaque
and endothelial function.
 
39
 
 This possibility is con-
sistent with results from the HOPE trial showing
that ACE inhibitors are beneficial in subjects with
high cardiovascular risk, despite minimal change in
blood pressure.
 
20
 
 Other possible mechanisms in-
clude the absence of any adverse effect on circu-
lating lipids,
 
12,13
 
 reduction of left ventricular hy-
pertrophy,
 
11
 
 greater likelihood of survival in the
presence of cardiac failure,
 
9
 
 reduced left ventricu-
lar function,
 
40
 
 enhanced insulin sensitivity,
 
13
 
 and
preservation of the glomerular filtration rate.
 
41-43
 
Substudies of our study concerning ambulatory
monitoring of blood pressure, left ventricular hy-
pertrophy, and vascular compliance may provide ev-
idence clarifying the mechanisms of the putative
benefit of ACE-inhibitor therapy beyond its effect
on blood pressure.
The reason for discrepant observations concern-
ing the relation between ACE-inhibitor treatment
and cause-specific end points — with a greater like-
lihood that a stroke will be fatal but a lower likeli-
hood of myocardial infarction — is not obvious. An
indication that the benefit of treatment does relate
to the reduction of the effects of angiotensin II
comes from the results of the LIFE study,
 
21
 
 which
demonstrated a reduction in cardiovascular events
or death from cardiovascular causes of 13 percent
(95 percent confidence interval, 2 to 23 percent)
with losartan as compared with atenolol, despite an
equivalent reduction in blood pressure.
In conclusion, in elderly subjects with hyperten-
sion, particularly among male subjects, ACE-inhib-
itor–based therapy resulted in an outcome advan-
tage over a diuretic-based regimen, despite similar
reductions in blood pressure. This finding was ob-
served in family practices, where most elderly per-
sons with hypertension receive their care. The ques-
tion of whether the relative benefit of beginning
treatment with an ACE-inhibitor–based regimen is
confined to men requires examination in large, on-
going trials.
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appendix
 
The following persons participated in the Second Australian National Blood Pressure Study: 
 
Regional Coordinating Centers:
 
 M. Nelson, A.
Bruce, P. Beckinsale, J. Thompson, M. McMurchie, G. Fraser, D. Gleave, V. Cope, F. DeLooze, S. Moore, C. Dibben, J. Newbury; 
 
Data Man-
agement and National Coordinating Centers:
 
 H. Miles, B. McDermott, K. Willson, C. Bear; 
 
Genetic Subcommittee:
 
 M. West, S. Harrap, C. Johnston,
L. Beilin, P. Ryan, L. Wing, C. Reid; 
 
Ambulatory Blood Pressure Monitoring Subcommittee:
 
 L. Beilin, M. Brown, P. Ryan, L. Wing, C. Reid; 
 
Left Ven-
tricular Hypertrophy Subcommittee:
 
 G. Jennings, P. Fletcher, M. Feneley, E. Dewar, L. Wing, C. Reid; 
 
Data Audit Subcommittee:
 
 J. McNeil, L. Wing,
J. Marley, C. Reid; 
 
Finance Subcommittee: 
 
C. Johnston, G. Jennings, L. Wing, C. Reid; 
 
Health Economic–Quality-of-Life Subcommittee:
 
 J. Marley, J.
Moss, P. Webb, P. Glasziou, F. Boyle, J. Primrose, L. Wing, C. Reid; 
 
Family Practitioner Advisory Committee:
 
 I. Steven, L. Piterman, F. De Looze,
J. Dickinson, J. Gambrill, P. Joseph, C. Reid; 
 
End-Point Committee:
 
 D. Hunt, G. Donnan, L. Wing, T. Morgan; 
 
Independent Data Audit Subcommit-
tee:
 
 J. Chalmers, J. Whitworth, S. MacMahon, C. Silagy (deceased).
The list of family-practice investigators who participated in the study can be found in Supplementary Appendix 1 (available with the
complete text of this article at http://www.nejm.org).
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